Change

Consolidated statement of income

for the year ended December 31


In € millions

 

 

 

 

 

Note

 

20081

 

2009

 

 

 

 

 

 

1

Restated for comparative presentation.

Continuing operations

 

 

 

 

 

Revenue

 

 

15,415

 

13,893

Cost of sales

 

 

(9,796)

 

(8,431)

Gross profit

 

 

5,619

 

5,462

 

 

 

 

 

 

Selling expenses

 

(3,387)

 

(3,211)

 

Impairment of ICI intangibles

 

(1,275)

 

 

General and administrative expenses

 

(1,108)

 

(1,091)

 

Research and development expenses

 

(353)

 

(338)

 

Other operating income/(expenses)

4

(73)

 

48

 

 

 

 

(6,196)

 

(4,592)

Operating income/(loss)

 

 

(577)

 

870

 

 

 

 

 

 

Financing income

5

 

154

 

62

Financing expenses related to pensions

5

 

(49)

 

(174)

Other financing expenses

5

 

(337)

 

(297)

Results from associates and joint ventures

11

 

25

 

22

Profit/(loss) before tax

 

 

(784)

 

483

 

 

 

 

 

 

Income tax

6

 

(260)

 

(128)

Profit/(loss) for the period from continuing operations

 

 

(1,044)

 

355

 

 

 

 

 

 

Discontinued operations

 

 

 

 

 

Profit for the period from discontinued operations

7

 

23

 

7

 

 

 

 

 

 

Profit/(loss) for the period

 

 

(1,021)

 

362

 

 

 

 

 

 

Attributable to:

 

 

 

 

 

- Shareholders of the company

 

 

(1,086)

 

285

- Minority interests

 

 

65

 

77

 

 

 

 

 

 

Profit/(loss) for the period

 

 

(1,021)

 

362

 

 

 

 

 

 

Earnings per share, in €

 

 

 

 

 

Continuing operations:

 

 

 

 

 

- Basic

16

 

(4.47)

 

1.20

- Diluted

16

 

(4.45)

 

1.18

Discontinued operations:

 

 

 

 

 

- Basic

16

 

0.09

 

0.03

- Diluted

16

 

0.09

 

0.03

Total operations:

 

 

 

 

 

- Basic

16

 

(4.38)

 

1.23

- Diluted

16

 

(4.36)

 

1.21

Keyword Search
Copyright © 2010 Akzo Nobel N.V.